UCK2

Existing Annotations Review

GO Term	Evidence	Action	Reason
GO:0005737 cytoplasm	IBA GO_REF:0000033	ACCEPT	Summary: IBA annotation correctly places UCK2 in the cytoplasm. Multiple lines of evidence confirm cytoplasmic localization, including Reactome annotation as cytosolic enzyme and experimental data showing cytosol localization in transfected cells. Reason: Consistent with experimental evidence from multiple sources confirming cytoplasmic/cytosolic localization. UniProt CC line states function occurs in cytoplasm, Reactome describes enzyme as cytosolic, and direct fluorescence microscopy shows cytosol localization. Supporting Evidence: PMID:27239701 Subcellular localization studies showed that UCK1-GFP and UCK2-GFP were localized in the cell nucleus and cytosol, respectively. Reactome:R-HSA-109903 Cytosolic uridine-cytidine kinase 2 (UCK2) catalyzes the reactions of cytidine or uridine with ATP to form CMP or UMP and ADP file:human/UCK2/UCK2-deep-research-perplexity-lite.md See deep research file for comprehensive analysis file:human/UCK2/UCK2-deep-research-falcon.md cytosolic pyrimidine nucleoside salvage
GO:0004849 uridine kinase activity	IBA GO_REF:0000033	ACCEPT	Summary: IBA annotation for uridine kinase activity is well-supported. UCK2 catalyzes phosphorylation of uridine to UMP using ATP. This is one of the two core catalytic activities of UCK2. Reason: This represents a core molecular function of UCK2, supported by direct experimental evidence and multiple independent studies. UniProt catalytic activity annotation confirms this function with EC 2.7.1.48. Supporting Evidence: PMID:11306702 The enzymes did not phosphorylate deoxyribonucleosides or purine ribonucleosides. UCK1 mRNA was detected as two isoforms... The enzymes phosphorylated several of the analogs, such as 6-azauridine, 5-fluorouridine PMID:27239701 Uridine-cytidine kinase (UCK) catalyzes the phosphorylation of uridine and cytidine file:human/UCK2/UCK2-deep-research-falcon.md Human UCK2 (UniProt Q9BZX2; EC 2.7.1.48) catalyzes ATP-dependent phosphorylation of the pyrimidine ribonucleosides uridine and cytidine to UMP and CMP, respectively, constituting the first/rate-limiting step of pyrimidine ribonucleoside salvage in many settings.
GO:0009224 CMP biosynthetic process	IEA GO_REF:0000108	MODIFY	Summary: IEA annotation for CMP biosynthetic process based on logical inference from cytidine kinase activity. While technically correct (UCK2 does synthesize CMP from cytidine), this term is overly general as it does not distinguish between de novo and salvage pathways. The more specific term GO:0044211 (CTP salvage) better captures UCK2's specific role in the salvage pathway. Reason: The term is too general and does not accurately reflect that UCK2 functions specifically in the salvage pathway, not de novo biosynthesis. UCK2 catalyzes cytidine + ATP to CMP + ADP, which is the first step of CTP salvage. The annotation should use GO:0044211 (CTP salvage) which is already present with IDA evidence. Proposed replacements: CTP salvage Supporting Evidence: PMID:11306702 shown to catalyze the phosphorylation of Urd and Cyd file:human/UCK2/UCK2-uniprot.txt Pyrimidine metabolism; CTP biosynthesis via salvage pathway; CTP from cytidine: step 1/3
GO:0000166 nucleotide binding	IEA GO_REF:0000043	MARK AS OVER ANNOTATED	Summary: This is a very general molecular function term. While UCK2 does bind nucleotides (ATP/GTP as phosphate donors, and uridine/cytidine substrates), this annotation is too non-specific to be informative. The more specific ATP binding term (GO:0005524) is already present. Reason: This term is too general and does not provide meaningful information about UCK2 specific function. The GO:0005524 (ATP binding) annotation is more informative and specific. Nucleotide binding is implied by the kinase activity annotations. Supporting Evidence: PMID:11306702 named UCK1 and UCK2, were expressed in Escherichia coli and shown to catalyze the phosphorylation of Urd and Cyd
GO:0004849 uridine kinase activity	IEA GO_REF:0000120	ACCEPT	Summary: Duplicate annotation of uridine kinase activity with different evidence code. This IEA annotation is redundant with the IBA and IDA annotations for the same term. Reason: While redundant, computational annotations can coexist with experimental ones. The annotation is correct and represents a core function of UCK2. Supporting Evidence: PMID:11306702 The enzymes did not phosphorylate deoxyribonucleosides or purine ribonucleosides... catalyze the phosphorylation of Urd and Cyd
GO:0005524 ATP binding	IEA GO_REF:0000120	ACCEPT	Summary: UCK2 uses ATP (or GTP) as a phosphate donor in its kinase reactions. Crystal structures show ATP binding sites. This is an essential component of UCK2 catalytic mechanism. Reason: ATP binding is a core molecular function required for UCK2 kinase activity. Supported by structural data showing ATP binding sites and biochemical evidence that ATP serves as phosphate donor. Supporting Evidence: Reactome:R-HSA-109903 cytidine or uridine with ATP to form CMP or UMP and ADP file:human/UCK2/UCK2-deep-research-falcon.md with ATP serving as the phosphate donor.
GO:0016301 kinase activity	IEA GO_REF:0000120	MARK AS OVER ANNOTATED	Summary: General kinase activity term that is less specific than the actual uridine kinase and cytidine kinase activities already annotated. While technically correct, it provides little additional information. Reason: This is a parent term of the more specific uridine kinase and cytidine kinase activities. The specific terms (GO:0004849, GO:0043771) provide more informative annotations. General parent terms like this are often automatically inferred but do not add functional specificity. Supporting Evidence: PMID:11306702 shown to catalyze the phosphorylation of Urd and Cyd
GO:0016740 transferase activity	IEA GO_REF:0000043	MARK AS OVER ANNOTATED	Summary: Extremely general molecular function term. Kinases are indeed transferases (transferring phosphate groups), but this term is far too broad to be informative about UCK2 specific function. Reason: This is a very high-level parent term that provides minimal functional information. The specific kinase activity terms are far more informative. Such general terms are typically auto-generated but do not contribute meaningful biological insight. Supporting Evidence: PMID:11306702 catalyze the phosphorylation of Urd and Cyd
GO:0043771 cytidine kinase activity	IEA GO_REF:0000120	ACCEPT	Summary: Cytidine kinase activity is one of the two core catalytic activities of UCK2, converting cytidine to CMP. This is well-documented experimentally. Reason: This represents a core molecular function of UCK2, equally important as its uridine kinase activity. Both activities are confirmed by direct biochemical assays and structural studies. Supporting Evidence: PMID:11306702 catalyze the phosphorylation of Urd and Cyd. The enzymes did not phosphorylate deoxyribonucleosides or purine ribonucleosides file:human/UCK2/UCK2-deep-research-falcon.md UCK2 is selective for pyrimidine ribonucleosides and does not phosphorylate purine ribonucleosides or 2′-deoxyribonucleosides
GO:0007631 feeding behavior	IEA GO_REF:0000107	REMOVE	Summary: This annotation appears to be a computational transfer from orthologs and is likely spurious for UCK2. There is no literature evidence connecting UCK2 to feeding behavior, and this seems implausible for a cytosolic nucleoside kinase involved in nucleotide metabolism. Reason: No supporting evidence for UCK2 involvement in feeding behavior. This appears to be an incorrect orthology-based inference. The deep research and all publications focus on nucleotide metabolism, cancer biology, and drug activation, with no mention of feeding behavior. The falcon deep research, which surveyed foundational enzymology through 2024 cancer/antiviral literature, likewise describes UCK2 exclusively as a pyrimidine ribonucleoside salvage kinase with no feeding-behavior role, reinforcing that this is a false positive from automated annotation transfer. Supporting Evidence: file:human/UCK2/UCK2-deep-research-falcon.md Human UCK2 (UniProt Q9BZX2; EC 2.7.1.48) catalyzes ATP-dependent phosphorylation of the pyrimidine ribonucleosides uridine and cytidine to UMP and CMP, respectively, constituting the first/rate-limiting step of pyrimidine ribonucleoside salvage in many settings.
GO:0048678 response to axon injury	IEA GO_REF:0000107	UNDECIDED	Summary: This annotation is based on automated ortholog transfer. While UCK2 is expressed in neural tissues and has been studied in neuroblastoma, there is no direct evidence linking it to axon injury response. This may be an overly specific inference from expression data. Reason: No direct experimental evidence in the available literature for UCK2 role in axon injury response. The neuroblastoma study focuses on UCK2 role in pyrimidine metabolism and drug sensitivity, not axon injury. Would need access to the original ortholog study (GO_REF:0000107) to evaluate this claim properly.
GO:0071453 cellular response to oxygen levels	IEA GO_REF:0000107	UNDECIDED	Summary: This annotation comes from automated ortholog transfer. There is no direct evidence in the available literature connecting UCK2 to oxygen level response. While UCK2 is overexpressed in various cancers which may involve hypoxic conditions, this is not the same as having a specific role in oxygen level response. Reason: No direct experimental evidence in available publications for UCK2 role in cellular response to oxygen levels. Would need to access the original reference and any supporting ortholog data to properly evaluate this annotation. The cancer association does not necessarily imply a direct oxygen response function.
GO:0042802 identical protein binding	IPI PMID:32296183 A reference map of the human binary protein interactome.	ACCEPT	Summary: This IPI annotation comes from the HuRI human reference interactome study, a large-scale yeast two-hybrid screen that detected UCK2 self-interaction. This is fully consistent with crystallographic data showing UCK2 functions as a homotetramer in its active form. Reason: UCK2 forms homotetramers, which necessarily involves identical protein binding. This is strongly supported by X-ray crystallographic structures (PDB entries 1UDW, 1UEI, 1UEJ, 1UFQ, etc.) showing the tetrameric assembly and the HuRI binary interaction data confirming self-interaction. The functional oligomerization state is well-established as essential for enzymatic activity. Supporting Evidence: PMID:32296183 (#)Contributed equally Global insights into cellular organization and genome function require comprehensive understanding of the interactome networks that mediate genotype-phenotype relationships1,2 file:human/UCK2/UCK2-uniprot.txt SUBUNIT: Homotetramer file:human/UCK2/UCK2-deep-research-falcon.md UCK2 is a ~29 kDa, 261-aa enzyme in the NMP kinase-fold family that forms a homotetramer
GO:0044206 UMP salvage	IEA GO_REF:0000120	ACCEPT	Summary: UMP salvage is a core biological process function of UCK2. The enzyme catalyzes the first and only step in converting uridine to UMP in the salvage pathway. Reason: This is a core biological process for UCK2, converting uridine to UMP in the salvage pathway. Well-supported by experimental data and pathway annotations. This is redundant with IDA annotations below but represents accurate function. Supporting Evidence: PMID:11306702 catalyze the phosphorylation of Urd and Cyd Reactome:R-HSA-109903 cytidine or uridine with ATP to form CMP or UMP and ADP file:human/UCK2/UCK2-deep-research-falcon.md UCK2 catalyzes the first committed phosphorylation step
GO:0044211 CTP salvage	IEA GO_REF:0000120	ACCEPT	Summary: CTP salvage is a core biological process function of UCK2. UCK2 catalyzes the first step (cytidine to CMP) in the three-step salvage pathway converting cytidine to CTP. Reason: This is a core biological process for UCK2. The enzyme performs the first step in the salvage pathway that recycles cytidine into CTP. Well-supported by experimental evidence and pathway databases. Redundant with IDA annotation below but accurate. Supporting Evidence: PMID:11306702 catalyze the phosphorylation of Urd and Cyd Reactome:R-HSA-109903 cytidine or uridine with ATP to form CMP or UMP and ADP file:human/UCK2/UCK2-deep-research-falcon.md UCK2 catalyzes the first committed phosphorylation step
GO:0004849 uridine kinase activity	IDA PMID:27239701 The pivotal role of uridine-cytidine kinases in pyrimidine m...	ACCEPT	Summary: Direct experimental evidence for uridine kinase activity from neuroblastoma study. This IDA annotation provides strong experimental support for this core function. Reason: Excellent experimental support from direct assay. This is a core molecular function of UCK2. The IDA evidence code indicates direct biochemical demonstration of this activity. Supporting Evidence: PMID:27239701 Uridine-cytidine kinase (UCK) catalyzes the phosphorylation of uridine and cytidine as well as the pharmacological activation of several cytotoxic pyrimidine ribonucleoside analogues
GO:0044206 UMP salvage	IDA PMID:27239701 The pivotal role of uridine-cytidine kinases in pyrimidine m...	ACCEPT	Summary: Direct experimental evidence for UMP salvage from neuroblastoma study showing UCK2 metabolizes uridine. Strong experimental support for this core biological process. Reason: Excellent experimental support from direct functional assays in neuroblastoma cells. The study directly measured uridine metabolism via UCK2, demonstrating its role in UMP salvage. This is a core biological process for UCK2. Supporting Evidence: PMID:27239701 Transient and stable overexpression of UCK2 in neuroblastoma cells increased the metabolism of uridine and cytidine
GO:0004849 uridine kinase activity	IDA PMID:11306702 Phosphorylation of uridine and cytidine nucleoside analogs b...	ACCEPT	Summary: Direct experimental evidence from the original cloning and characterization study. This is the foundational paper demonstrating UCK2 uridine kinase activity. Reason: This is the primary experimental characterization of UCK2 uridine kinase activity from the original cloning study. Direct biochemical demonstration of this core molecular function with recombinant enzyme. Supporting Evidence: PMID:11306702 The approximately 30-kDa proteins, named UCK1 and UCK2, were expressed in Escherichia coli and shown to catalyze the phosphorylation of Urd and Cyd. The enzymes did not phosphorylate deoxyribonucleosides or purine ribonucleosides
GO:0043771 cytidine kinase activity	IDA PMID:11306702 Phosphorylation of uridine and cytidine nucleoside analogs b...	ACCEPT	Summary: Direct experimental evidence from the original characterization study. This established cytidine kinase as one of the two core activities of UCK2. Reason: Foundational experimental demonstration of UCK2 cytidine kinase activity from the original cloning and characterization study. Direct biochemical evidence with recombinant enzyme. This is a core molecular function. Supporting Evidence: PMID:11306702 shown to catalyze the phosphorylation of Urd and Cyd. The enzymes did not phosphorylate deoxyribonucleosides or purine ribonucleosides
GO:0044206 UMP salvage	IDA PMID:11306702 Phosphorylation of uridine and cytidine nucleoside analogs b...	ACCEPT	Summary: Direct experimental evidence for UMP salvage function from the original characterization showing uridine phosphorylation. This demonstrated UCK2 role in the salvage pathway. Reason: Excellent experimental support from the foundational study. Direct demonstration that UCK2 phosphorylates uridine to UMP, which is the salvage pathway for UMP biosynthesis. This is a core biological process. Supporting Evidence: PMID:11306702 catalyze the phosphorylation of Urd and Cyd. The enzymes did not phosphorylate deoxyribonucleosides or purine ribonucleosides
GO:0044211 CTP salvage	IDA PMID:11306702 Phosphorylation of uridine and cytidine nucleoside analogs b...	ACCEPT	Summary: Direct experimental evidence for CTP salvage from the original study showing cytidine phosphorylation. UCK2 performs the first step in the CTP salvage pathway. Reason: Strong experimental support from the foundational characterization study. Direct demonstration that UCK2 phosphorylates cytidine to CMP, the first step in CTP salvage pathway. This is a core biological process. Supporting Evidence: PMID:11306702 catalyze the phosphorylation of Urd and Cyd
GO:0005829 cytosol	TAS Reactome:R-HSA-109903	ACCEPT	Summary: TAS (Traceable Author Statement) annotation based on Reactome pathway annotation. Reactome describes UCK2 as cytosolic. This is consistent with experimental localization data. Reason: Cytosol localization is well-supported by Reactome annotation and experimental evidence. While cytosol is a more specific term than cytoplasm (GO:0005737), both are appropriate. The TAS evidence from Reactome is reliable for subcellular localization. Supporting Evidence: Reactome:R-HSA-109903 Cytosolic uridine-cytidine kinase 2 (UCK2) catalyzes the reactions of cytidine or uridine with ATP to form CMP or UMP and ADP PMID:27239701 Subcellular localization studies showed that UCK1-GFP and UCK2-GFP were localized in the cell nucleus and cytosol, respectively
GO:0005525 GTP binding	IDA PMID:11306702 Phosphorylation of uridine and cytidine nucleoside analogs b...	NEW	Summary: UCK2 can use GTP as an alternative phosphate donor in addition to ATP. This is documented in the original characterization study and in UniProt. While ATP is the primary phosphate donor, GTP binding represents an additional molecular function that provides metabolic flexibility. Reason: This represents a documented molecular function that is not currently annotated. The ability to use GTP as a phosphate donor is explicitly stated in UniProt and the original characterization paper. While less prominent than ATP binding, it represents a genuine alternative cofactor usage that should be annotated. Supporting Evidence: file:human/UCK2/UCK2-uniprot.txt Can use ATP or GTP as a phosphate donor PMID:11306702 shown to catalyze the phosphorylation of Urd and Cyd

Core Functions

ATP-dependent phosphorylation of uridine to UMP in pyrimidine salvage pathway

Molecular Function:

uridine kinase activity

Directly Involved In:

UMP salvage

Cellular Locations:

cytosol

Substrates:

uridine ATP(4-)

Supporting Evidence:

PMID:11306702
The approximately 30-kDa proteins, named UCK1 and UCK2, were expressed in Escherichia coli and shown to catalyze the phosphorylation of Urd and Cyd
PMID:27239701
Uridine-cytidine kinase (UCK) catalyzes the phosphorylation of uridine and cytidine as well as the pharmacological activation of several cytotoxic pyrimidine ribonucleoside analogues
Reactome:R-HSA-109903
Cytosolic uridine-cytidine kinase 2 (UCK2) catalyzes the reactions of cytidine or uridine with ATP to form CMP or UMP and ADP
file:human/UCK2/UCK2-deep-research-falcon.md
Human UCK2 (UniProt Q9BZX2; EC 2.7.1.48) catalyzes ATP-dependent phosphorylation of the pyrimidine ribonucleosides uridine and cytidine to UMP and CMP, respectively, constituting the first/rate-limiting step of pyrimidine ribonucleoside salvage in many settings.

ATP-dependent phosphorylation of cytidine to CMP in pyrimidine salvage pathway

Molecular Function:

cytidine kinase activity

Directly Involved In:

CTP salvage

Cellular Locations:

cytosol

Substrates:

cytidine ATP(4-)

Supporting Evidence:

PMID:11306702
shown to catalyze the phosphorylation of Urd and Cyd. The enzymes did not phosphorylate deoxyribonucleosides or purine ribonucleosides
PMID:27239701
Transient and stable overexpression of UCK2 in neuroblastoma cells increased the metabolism of uridine and cytidine
Reactome:R-HSA-109903
Cytosolic uridine-cytidine kinase 2 (UCK2) catalyzes the reactions of cytidine or uridine with ATP to form CMP or UMP and ADP
file:human/UCK2/UCK2-deep-research-falcon.md
UCK2 is selective for pyrimidine ribonucleosides and does not phosphorylate purine ribonucleosides or 2′-deoxyribonucleosides

References

GO_REF:0000033

Annotation inferences using phylogenetic trees

GO_REF:0000043

Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping

GO_REF:0000107

Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara.

GO_REF:0000108

Automatic assignment of GO terms using logical inference, based on on inter-ontology links.

GO_REF:0000120

Combined Automated Annotation using Multiple IEA Methods.

PMID:11306702

Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases.

PMID:27239701

The pivotal role of uridine-cytidine kinases in pyrimidine metabolism and activation of cytotoxic nucleoside analogues in neuroblastoma.

PMID:32296183

A reference map of the human binary protein interactome.

Reactome:R-HSA-109903

cytidine or uridine + ATP => CMP or UMP + ADP [UCK2]

file:human/UCK2/UCK2-deep-research-perplexity-lite.md

Deep research on UCK2 function

file:human/UCK2/UCK2-deep-research-falcon.md

Falcon deep research for human UCK2 (Q9BZX2)

UCK2 catalyzes the first committed, ATP-dependent phosphorylation step of pyrimidine ribonucleoside salvage, converting uridine to UMP and cytidine to CMP. This step is functionally rate-limiting for ribonucleoside salvage.

"UCK2 catalyzes the first committed phosphorylation step"
Substrate specificity is restricted to pyrimidine ribonucleosides: UCK2 does not phosphorylate purine ribonucleosides (adenosine/guanosine) or 2'-deoxyribonucleosides, and accepts ribonucleoside analogs but not sugar-modified analogs such as araC, consistent with a ribose-OH requirement.

"UCK2 is selective for pyrimidine ribonucleosides and does not phosphorylate purine ribonucleosides or 2′-deoxyribonucleosides"
UCK2 has lower Km and higher Vmax (and thus markedly higher catalytic efficiency) for uridine and cytidine than the paralog UCK1.

"Compared with UCK1, UCK2 has lower Km and higher Vmax for uridine/cytidine"
UCK2 is a ~29 kDa, 261-residue enzyme of the NMP kinase fold that functions as a homotetramer, with crystal structures showing ligand-free, substrate/ product-bound, and feedback-inhibited tetrameric states.

"UCK2 is a ~29 kDa, 261-aa enzyme in the NMP kinase-fold family that forms a homotetramer"
UCK2 is allosterically regulated: activated by ATP and feedback-inhibited by the downstream products UTP and CTP; a distinct intersubunit allosteric pocket has been described where noncompetitive inhibitors reduce kcat without changing Km.

"UCK2 is activated by ATP and feedback-inhibited by UTP and CTP."
Localization is described as cytosolic pyrimidine nucleoside salvage, but the retrieved evidence set does not include direct microscopy-based localization experiments, so cytosolic localization is treated as a pathway-context inference.

"does not include direct microscopy-based localization experiments"
UCK2 is tissue-restricted in normal tissues (placenta/testis) but broadly upregulated across many cancers, motivating tumor-selective activation of cytotoxic nucleoside analogs (e.g., RX-3117) that depend on UCK2 phosphorylation.

"later translational studies and reviews describe expression in placenta/testis and broad upregulation across many cancers"

Deep Research

Falcon

(UCK2-deep-research-falcon.md)

this with annotations you find in gene/protein databases, but these can be outdated or inaccurate. Falcon Edison Scientific Literature 48 citations 2 artifacts 2026-05-30T02:29:50.205240

Edison artifact artifact-00 (text/markdown)

## Context ID: pqac-00000017 The following figures and tables from the paper describe the structure, tetramerization, active site, and feedback inhibition of hu (image/png)

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: Human UCK2 (UniProt Q9BZX2) — Functional Annotation, Recent Research, and Applications

0) Target verification (gene/protein identity)

The evidence summarized here pertains specifically to human uridine–cytidine kinase 2 (UCK2; EC 2.7.1.48), corresponding to UniProt Q9BZX2, a pyrimidine ribonucleoside kinase that forms a homotetramer and is distinct from the related enzymes UCK1 and UCKL1. This specificity is explicit in primary structural work on human UCK2 and in pharmacologic studies using UCK2-targeting knockdown/biochemical assays. (suzuki2004structuralbasisfor pages 1-3, sarkisjan2016thecytidineanalog pages 1-2, mashayekh2022structurebasedprototypingof pages 6-12)

1) Key concepts and definitions (current understanding)

1.1 Pyrimidine nucleoside salvage and “rate-limiting” first phosphorylation

Pyrimidine salvage refers to recovery of pyrimidine nucleosides (notably uridine and cytidine) from extracellular sources or nucleic-acid turnover, converting them back into nucleotide pools. UCK2 catalyzes the first committed phosphorylation step, converting nucleosides to nucleoside monophosphates, which can then be further phosphorylated to di- and triphosphates for incorporation into RNA/DNA or other metabolic uses. This first phosphorylation step is often described as functionally rate-limiting for ribonucleoside salvage. (suzuki2004structuralbasisfor pages 1-3, okesliarmlovich2019discoveryofsmall pages 1-3)

1.2 Enzymatic reaction catalyzed by UCK2

Human UCK2 catalyzes ATP-dependent phosphorylation of the pyrimidine ribonucleosides:
- Uridine → UMP
- Cytidine → CMP
with ATP serving as the phosphate donor. (suzuki2004structuralbasisfor pages 1-3, rompay2001phosphorylationofuridine pages 3-4)

2) Core molecular function: substrates, specificity, and kinetics

2.1 Substrate class specificity (ribo vs deoxy; pyrimidine vs purine)

Recombinant human UCK1 and UCK2 both phosphorylate uridine and cytidine, and do not phosphorylate purine ribonucleosides (adenosine/guanosine) or 2′-deoxyribonucleosides under tested conditions, supporting stringent selection for pyrimidine ribonucleosides. (rompay2001phosphorylationofuridine pages 3-4, suzuki2004structuralbasisfor pages 1-3)

2.2 Quantitative kinetic differences: UCK2 vs UCK1

In a foundational comparative enzymology study (van Rompay et al., 2001), UCK2 exhibited:
- Lower Km for uridine and cytidine than UCK1 (approx. 4–6× lower), and
- Higher Vmax, resulting in markedly higher catalytic efficiency (kcat/Km) for UCK2 than UCK1. (rompay2001phosphorylationofuridine pages 3-4)

2.3 Nucleoside analog phosphorylation (drug/probe activation)

UCK2 phosphorylates a range of uridine/cytidine nucleoside analogs, enabling their conversion into active nucleotide metabolites. A broad panel tested in recombinant enzymes showed phosphorylation of multiple base-modified analogs (selected examples):
- 6-azauridine (UCK1 & UCK2)
- 6-azacytidine (reported as UCK2-only in that screen)
- 5-fluorouridine, 4-thiouridine, 5-bromouridine, and multiple N4-substituted cytidines (various tolerances)
while sugar-modified cytidine analogs such as araC and certain deoxy/dideoxy analogs were not substrates, consistent with ribose-OH requirements. (rompay2001phosphorylationofuridine pages 3-4)

Primary structural work also notes phosphorylation of cytotoxic ribonucleoside analogs including 5-fluorouridine and cyclopentenyl-cytidine derivatives as UCK substrates. (suzuki2004structuralbasisfor pages 1-3)

3) Structure, catalytic mechanism, and regulation

3.1 Oligomeric state and fold

Human UCK2 adopts an NMP kinase-like fold and functions as a homotetramer. Crystal structures support tetrameric assemblies and show ligand-dependent conformational states. (suzuki2004structuralbasisfor pages 1-3, suzuki2004structuralbasisfor pages 4-6)

Visual evidence from the foundational structural paper illustrates tetrameric states and ligand-binding conformational changes, including inhibitor-bound states and remodeling of the acceptor-site cavity. (suzuki2004structuralbasisfor media fedd12be, suzuki2004structuralbasisfor media da16ea3f, suzuki2004structuralbasisfor media 76e0d74f, suzuki2004structuralbasisfor media 4a76c853)

3.2 Induced fit and binding-site remodeling

Comparison of ligand-free versus ligand-bound structures indicates substantial induced-fit conformational change particularly around the acceptor (nucleoside) binding site, whereas the ATP-binding site remains comparatively constant across several ligand-bound structures. (suzuki2004structuralbasisfor pages 4-6)

3.3 Feedback inhibition and nucleotide regulation

UCK2 is described as:
- Activated by ATP, and
- Feedback-inhibited by UTP and CTP, with structural evidence from inhibitor-bound complexes and biochemical analyses. (suzuki2004structuralbasisfor pages 1-3, mashayekh2022structurebasedprototypingof pages 6-12)

3.4 Allosteric inhibition: new structural insights (drug discovery relevance)

Structure-based inhibitor prototyping identified a previously unrecognized allosteric site at the inter-subunit interface of tetrameric UCK2. These inhibitors act non-competitively (relative to uridine and ATP) and primarily reduce kcat without substantially changing Km, enabling “dialing” down salvage flux. (mashayekh2022structurebasedprototypingof pages 1-6, mashayekh2022structurebasedprototypingof pages 6-12)

4) Cellular localization and pathway context

4.1 Subcellular location (evidence-limited)

In the retrieved corpus, UCK2 is consistently discussed as functioning in cytosolic pyrimidine nucleoside salvage (e.g., converting extracellular/plasma-derived nucleosides into nucleotide pools), but the current evidence set does not include direct microscopy-based localization experiments (e.g., immunofluorescence or cell fractionation with UCK2 detection). Thus, cytosolic localization is best treated as a pathway-context inference from salvage biology rather than definitively demonstrated here. (okesliarmlovich2019discoveryofsmall pages 1-3, mashayekh2022structurebasedprototypingof pages 1-6)

4.2 Pathway interactions: salvage vs de novo synthesis

A recurring functional theme is the interaction between de novo pyrimidine synthesis (e.g., DHODH-dependent) and salvage (UCK2-dependent). When de novo synthesis is inhibited, salvage can compensate by phosphorylating extracellular uridine; therefore, combined targeting of DHODH and UCK2 has been proposed/validated in antiviral and metabolic intervention frameworks. (okesliarmlovich2019discoveryofsmall pages 1-3, mashayekh2022structurebasedprototypingof pages 6-12)

5) Expression patterns and regulation in normal tissues and cancer

5.1 Normal tissue expression (older panels) and tissue selectivity

In an early tissue panel, UCK2 mRNA isoforms were detected only in placenta among investigated tissues, whereas UCK1 showed broader expression, supporting the historical view of UCK2 as more tissue-restricted. (rompay2001phosphorylationofuridine pages 3-4)

Later translational work continues to describe UCK2 as limited in normal tissues (often placenta/testis) but upregulated in many tumors, motivating “tumor-selective activation” strategies. (hassouni2019uridinecytidinekinase pages 1-2, fu2022themetabolicand pages 2-4)

5.2 2023 evidence of tissue-context relevance for drug genotoxicity

A 2023 Nucleic Acids Research study (Xu et al., published Nov 2023, https://doi.org/10.1093/nar/gkad1002) reported that blood and liver have relatively low UCK2 expression compared with other tissues or cultured cells in referenced expression resources, which the authors discuss as potentially relevant for differences between in vitro mutagenicity results and in vivo genotoxicity assays for molnupiravir/NHC. (xu2023uridine–cytidinekinase2 pages 9-10)

5.3 Pan-cancer genomic patterns (2024)

A 2024 pan-cancer analysis of pyrimidine salvage genes reported that salvage-pathway genes generally show low mutation rates but notable copy-number variation, with UCK2 listed among genes showing amplifications across cancers; expression upregulation and correlations with clinical features/prognosis were also reported at a broad level (though quantitative UCK2-specific effect sizes were not extractable from the available excerpt). (li2024integrativeanalysesof pages 1-2)

6) Recent developments (prioritizing 2023–2024)

6.1 UCK2 and antiviral nucleoside analog metabolism/genotoxicity (2023)

Xu et al. (2023, Nucleic Acids Research) performed a CRISPR screen and found that inactivation of Uck2 increased cellular tolerance to β-d-N4-hydroxycytidine (NHC; active form of molnupiravir) and that UCK2 activity potentiated NHC-associated mutagenic outcomes in their cellular model; they further note that UCK2 phosphorylates multiple nucleoside analogs including azacytidine, fluorocyclopentenylcytosine, and 3′-ethynyl nucleosides. (xu2023uridine–cytidinekinase2 pages 9-10)

6.2 UCK2 induction in immune cell proliferation programs (2024)

Watanabe et al. (2024, Blood Advances; Mar 2024, https://doi.org/10.1182/bloodadvances.2023011131) report that UCK2 (but not UCK1) is overexpressed in HTLV-1–infected T cells/ATL contexts and supports vigorous proliferation; they also summarize that UCK proteins catalyze phosphorylation of uridine/cytidine during salvage. This places UCK2 within the broader reprogramming of pyrimidine metabolism in proliferative immune-cell states. (watanabe2024reprogrammingofpyrimidine pages 6-7)

6.3 UCK2 as a driver of tumor progression and chemotherapy response (2024)

Wu et al. (2024, Cell Death Discovery; Aug 2024, https://doi.org/10.1038/s41420-024-02140-x) report elevated UCK2 in intrahepatic cholangiocarcinoma and show that UCK2 overexpression promotes proliferation, migration/invasion, tumor growth, and cisplatin resistance, mechanistically linked to PI3K/AKT/mTOR signaling and autophagy inhibition. Higher UCK2 expression was associated with aggressive tumor features, poorer survival, and lower chemotherapy sensitivity in that cohort. (wu2024uck2promotesintrahepatic pages 1-2)

6.4 Post-transcriptional regulation via circRNA (2024)

Shen et al. (2024, Discover Oncology; Jan 2024, https://doi.org/10.1007/s12672-024-00863-y) describe a regulatory mechanism in hepatocellular carcinoma whereby circUCK2 acts as a ceRNA for miR-149-5p, thereby upregulating UCK2 and promoting proliferation/migration/invasion and tumor growth in vivo; rescue experiments support functional dependence on UCK2 expression. (shen2024circuck2promoteshepatocellular pages 1-3)

7) Current applications and real-world implementations

7.1 Precision oncology: UCK2 as a biomarker and drug-activation enzyme

RX-3117 (fluorocyclopentenylcytosine) is a cytidine analog whose activity depends on phosphorylation. In lung cancer cell lines, UCK2 knockdown (siRNA) “completely downregulated” UCK2 and protected cells against RX-3117; RX-3117 nucleotide accumulation and UCK activity correlated with UCK2 expression (reported correlations r = 0.803 and 0.915 in cell panels and xenografts). (sarkisjan2016thecytidineanalog pages 1-2)

In pancreatic cancer, a biomarker-focused study reported UCK2 protein expression was high in 21/25 tumors, and high UCK2 was associated with shorter mean overall survival (8.4 vs 34.3 months, p = 0.045), supporting UCK2 as a candidate patient-selection biomarker for UCK2-activated nucleoside analog therapy. (hassouni2019uridinecytidinekinase pages 1-2)

7.2 Host-directed antiviral strategies: targeting salvage with UCK2 inhibitors

Because salvage can rescue nucleotide pools when de novo synthesis is inhibited, UCK2 inhibitors have been developed to suppress uridine salvage. High-throughput screening identified multiple inhibitor classes, including non-competitive inhibitors with micromolar potency and cell-based effects on uridine analog uptake under DHODH inhibition conditions. (okesliarmlovich2019discoveryofsmall pages 4-6, okesliarmlovich2019discoveryofsmall pages 1-3)

Allosteric inhibitor discovery further suggests pharmacologic opportunities to modulate salvage flux by reducing kcat. (mashayekh2022structurebasedprototypingof pages 6-12, mashayekh2022structurebasedprototypingof pages 1-6)

8) Expert opinions and synthesis from authoritative sources

A 2022 mini-review synthesizes that UCK2’s tumor relevance may stem both from (i) its catalytic role supplying nucleotide building blocks via salvage and (ii) reported “non-metabolic” roles engaging oncogenic signaling pathways (e.g., STAT3; EGFR–AKT), and that leveraging UCK2 catalytic activity enables tumor-selective activation of cytotoxic ribonucleoside analogs such as RX-3117. (fu2022themetabolicand pages 1-2, fu2022themetabolicand pages 2-4)

A 2023 Nature Reviews Cancer review on nucleotide metabolism positions salvage enzymes including UCK1/UCK2 within pan-cancer dependencies and therapeutic opportunities, reinforcing the broader context in which UCK2 expression can be coupled to drug response and metabolic vulnerabilities (the excerpt available here confirms inclusion of UCK1/UCK2 in this conceptual framework). (suzuki2004structuralbasisfor pages 1-3)

9) Key statistics and quantitative data (from available evidence)

Enzyme kinetics comparison (recombinant): UCK2 shows ~4–6× lower Km and higher Vmax than UCK1 for uridine/cytidine; reported kcat/Km values for UCK2 in one assay were ~26×10^3 s−1·M−1 (uridine) and ~37×10^3 s−1·M−1 (cytidine) vs ~1.2×10^3 and ~2.0×10^3 for UCK1. (rompay2001phosphorylationofuridine pages 3-4)
Pancreatic cancer biomarker cohort: UCK2 protein high in 21/25 tumors; mean overall survival 8.4 vs 34.3 months (high vs low), p=0.045. (hassouni2019uridinecytidinekinase pages 1-2)
RX-3117 activation dependence: correlation of UCK2 expression with UCK activity and nucleotide accumulation reported as r=0.803 and r=0.915 in tumor cell/xenograft panels; UCK2 knockdown protects cells from RX-3117 cytotoxicity. (sarkisjan2016thecytidineanalog pages 1-2)
UCK2 inhibitor potency example: compound 20874830 reported with an IC50 in low micromolar range upon retesting and kinetic Ki values consistent with non-competitive inhibition (micromolar), with partial suppression of uridine salvage in cells at 50 µM. (okesliarmlovich2019discoveryofsmall pages 4-6)

10) Limitations of the retrieved evidence set (important for functional annotation)

Direct subcellular localization (e.g., cytosol vs nucleus vs organelles) was not directly demonstrated in the extracted passages; the report therefore treats localization primarily as pathway-context inference (salvage in cytosol) rather than definitive cell biology. (okesliarmlovich2019discoveryofsmall pages 1-3)
Some 2023–2024 cancer expression/prognosis claims (e.g., hazard ratios, fold-changes) could not be quantitatively extracted from the available excerpts for certain papers (e.g., pan-cancer TCGA analysis). (li2024integrativeanalysesof pages 1-2)

11) Consolidated evidence table

Functional aspect	Key findings	Key sources with year and DOI/URL
Reaction	Human UCK2 (UniProt Q9BZX2; EC 2.7.1.48) catalyzes ATP-dependent phosphorylation of the pyrimidine ribonucleosides uridine and cytidine to UMP and CMP, respectively, constituting the first/rate-limiting step of pyrimidine ribonucleoside salvage in many settings. Foundational structural and biochemical studies agree on this core activity. (suzuki2004structuralbasisfor pages 1-3, fu2022themetabolicand pages 1-2, okesliarmlovich2019discoveryofsmall pages 1-3)	Suzuki et al., 2004, Structure, doi:10.1016/j.str.2004.02.038, https://doi.org/10.1016/j.str.2004.02.038; Fu et al., 2022, Front Oncol, doi:10.3389/fonc.2022.904887, https://doi.org/10.3389/fonc.2022.904887; Okesli-Armlovich et al., 2019, Bioorg Med Chem Lett, doi:10.1016/j.bmcl.2019.08.010, https://doi.org/10.1016/j.bmcl.2019.08.010
Substrate specificity	UCK2 is selective for pyrimidine ribonucleosides and does not phosphorylate purine ribonucleosides or 2′-deoxyribonucleosides. Compared with UCK1, UCK2 has lower Km and higher Vmax for uridine/cytidine; reported catalytic efficiencies were ~26 × 10^3 s^-1 M^-1 for uridine and ~37 × 10^3 s^-1 M^-1 for cytidine in one recombinant assay, versus ~1.2 × 10^3 and ~2.0 × 10^3 for UCK1. Multiple analogs are accepted, including 6-azauridine, 5-fluorouridine, 4-thiouridine, 5-bromouridine, 5-fluorocytidine, 2-thiocytidine, 5-methylcytidine, and N4-substituted cytidines. (rompay2001phosphorylationofuridine pages 3-4, suzuki2004structuralbasisfor pages 1-3, fu2022themetabolicand pages 2-4)	Van Rompay et al., 2001, Mol Pharmacol, doi:10.1124/mol.59.5.1181, https://doi.org/10.1124/mol.59.5.1181; Suzuki et al., 2004, https://doi.org/10.1016/j.str.2004.02.038; Fu et al., 2022, https://doi.org/10.3389/fonc.2022.904887
Regulation / feedback inhibition	UCK2 is activated by ATP and feedback-inhibited by UTP and CTP. Structural studies showed inhibitor-bound states and conformational changes associated with ligand binding, while recent medicinal chemistry identified a distinct intersubunit allosteric pocket where noncompetitive inhibitors reduce kcat without materially changing Km. (suzuki2004structuralbasisfor pages 1-3, mashayekh2022structurebasedprototypingof pages 6-12, mashayekh2022structurebasedprototypingof pages 1-6, suzuki2004structuralbasisfor media fedd12be)	Suzuki et al., 2004, Structure, doi:10.1016/j.str.2004.02.038, https://doi.org/10.1016/j.str.2004.02.038; Mashayekh et al., 2022, Biochemistry, doi:10.1021/acs.biochem.2c00451, https://doi.org/10.1021/acs.biochem.2c00451
Structure / oligomerization	UCK2 is a ~29 kDa, 261-aa enzyme in the NMP kinase-fold family that forms a homotetramer. Crystal structures revealed ligand-free, substrate/product-bound, and feedback-inhibited tetrameric states, with induced-fit remodeling of the acceptor site; key residues highlighted across studies include Asp62 (catalytic base), Tyr112/His117 (base recognition), Asp84/Arg166 (ribose OH recognition), and Mg2+-coordinating residues. (suzuki2004structuralbasisfor pages 1-3, suzuki2004structuralbasisfor pages 4-6, fu2022themetabolicand pages 2-4, suzuki2004structuralbasisfor media fedd12be)	Suzuki et al., 2004, Structure, doi:10.1016/j.str.2004.02.038, https://doi.org/10.1016/j.str.2004.02.038; Fu et al., 2022, Front Oncol, doi:10.3389/fonc.2022.904887, https://doi.org/10.3389/fonc.2022.904887
Expression patterns	Foundational work detected UCK2 mRNA much more restrictively than UCK1, with placenta-specific detection in one early normal-tissue panel; later translational studies and reviews describe expression in placenta/testis and broad upregulation across many cancers. A 2023 mutagenesis study further noted that UCK2 expression is low in blood and liver relative to many cultured cells/tissues, potentially relevant to tissue-specific drug effects. (rompay2001phosphorylationofuridine pages 3-4, hassouni2019uridinecytidinekinase pages 1-2, xu2023uridine–cytidinekinase2 pages 9-10, li2024integrativeanalysesof pages 1-2)	Van Rompay et al., 2001, https://doi.org/10.1124/mol.59.5.1181; El Hassouni et al., 2019, AntiCancer Res, doi:10.21873/anticanres.13508, https://doi.org/10.21873/anticanres.13508; Xu et al., 2023, Nucleic Acids Res, doi:10.1093/nar/gkad1002, https://doi.org/10.1093/nar/gkad1002; Li et al., 2024, J Inflamm Res, doi:10.2147/JIR.S440295, https://doi.org/10.2147/jir.s440295
Cancer roles	UCK2 is repeatedly linked to malignant proliferation and metastasis, with both metabolic and reported non-metabolic signaling roles. Recent studies show overexpression in HTLV-1/ATL T cells supporting proliferation, and in intrahepatic cholangiocarcinoma promoting growth, migration/invasion, poorer survival, and cisplatin resistance via PI3K/AKT/mTOR-autophagy; pan-cancer analyses also report amplification/upregulation associations. (wu2024uck2promotesintrahepatic pages 1-2, li2024integrativeanalysesof pages 1-2, watanabe2024reprogrammingofpyrimidine pages 6-7, fu2022themetabolicand pages 1-2)	Watanabe et al., 2024, Blood Adv, doi:10.1182/bloodadvances.2023011131, https://doi.org/10.1182/bloodadvances.2023011131; Wu et al., 2024, Cell Death Discov, doi:10.1038/s41420-024-02140-x, https://doi.org/10.1038/s41420-024-02140-x; Li et al., 2024, https://doi.org/10.2147/jir.s440295; Fu et al., 2022, https://doi.org/10.3389/fonc.2022.904887
Drug activation / biomarker use	UCK2 phosphorylates and thereby activates several cytotoxic ribonucleoside analogs. Strongest cited translational evidence is for RX-3117, where UCK2 knockdown protected tumor cells and drug nucleotide accumulation correlated with UCK2 expression (r = 0.803 and 0.915 in cell panels/xenografts); in pancreatic cancer, high UCK2 protein was observed in 21/25 tumors and associated with shorter mean overall survival (8.4 vs 34.3 months, p = 0.045). UCK2 is also implicated in activation of azacytidine and other analogs, and chromosome 1q gains may create a UCK2-linked therapeutic vulnerability. (sarkisjan2016thecytidineanalog pages 1-2, hassouni2019uridinecytidinekinase pages 1-2, xu2023uridine–cytidinekinase2 pages 9-10)	Sarkisjan et al., 2016, PLoS ONE, doi:10.1371/journal.pone.0162901, https://doi.org/10.1371/journal.pone.0162901; El Hassouni et al., 2019, AntiCancer Res, doi:10.21873/anticanres.13508, https://doi.org/10.21873/anticanres.13508; Xu et al., 2023, https://doi.org/10.1093/nar/gkad1002
Antiviral context	In host-directed antiviral strategies, UCK2 is the salvage-pathway kinase whose activity can preserve pyrimidine pools when de novo synthesis is blocked, making it an attractive cotarget with DHODH. Small-molecule UCK2 inhibitors and allosteric leads have been developed to suppress uridine salvage, and 2023 work showed that UCK2 also potentiates mutagenic effects of β-d-N4-hydroxycytidine/molnupiravir in cells, with loss of UCK2 reducing mutagenicity. (okesliarmlovich2019discoveryofsmall pages 1-3, mashayekh2022structurebasedprototypingof pages 6-12, xu2023uridine–cytidinekinase2 pages 9-10)	Okesli-Armlovich et al., 2019, Bioorg Med Chem Lett, doi:10.1016/j.bmcl.2019.08.010, https://doi.org/10.1016/j.bmcl.2019.08.010; Mashayekh et al., 2022, Biochemistry, doi:10.1021/acs.biochem.2c00451, https://doi.org/10.1021/acs.biochem.2c00451; Xu et al., 2023, Nucleic Acids Res, doi:10.1093/nar/gkad1002, https://doi.org/10.1093/nar/gkad1002

Table: This table summarizes compact functional-annotation evidence for human UCK2/Q9BZX2 across enzymology, structure, regulation, expression, disease biology, and translational applications. It highlights both foundational mechanistic studies and recent 2023–2024 papers most relevant to current understanding.

12) Key primary sources (with publication dates and URLs)

Suzuki N. et al. (May 2004). Structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase. Structure. https://doi.org/10.1016/j.str.2004.02.038 (suzuki2004structuralbasisfor pages 1-3)
Van Rompay A.R. et al. (May 2001). Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Molecular Pharmacology. https://doi.org/10.1124/mol.59.5.1181 (rompay2001phosphorylationofuridine pages 3-4)
Xu Z. et al. (Nov 2023). Uridine–cytidine kinase 2 potentiates the mutagenic influence of the antiviral β-d-N4-hydroxycytidine. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad1002 (xu2023uridine–cytidinekinase2 pages 9-10)
Watanabe T. et al. (Mar 2024). Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells. Blood Advances. https://doi.org/10.1182/bloodadvances.2023011131 (watanabe2024reprogrammingofpyrimidine pages 6-7)
Wu X. et al. (Aug 2024). UCK2 promotes intrahepatic cholangiocarcinoma progression and desensitizes cisplatin treatment by PI3K/AKT/mTOR/autophagic axis. Cell Death Discovery. https://doi.org/10.1038/s41420-024-02140-x (wu2024uck2promotesintrahepatic pages 1-2)
Shen M. et al. (Jan 2024). CircUCK2 promotes hepatocellular carcinoma development by upregulating UCK2 in a miR-149-5p-dependent manner. Discover Oncology. https://doi.org/10.1007/s12672-024-00863-y (shen2024circuck2promoteshepatocellular pages 1-3)
Sarkisjan D. et al. (Sep 2016). RX-3117 is activated by uridine-cytidine kinase 2. PLOS ONE. https://doi.org/10.1371/journal.pone.0162901 (sarkisjan2016thecytidineanalog pages 1-2)
El Hassouni B. et al. (Jul 2019). UCK2 as a potential biomarker for RX-3117 in pancreatic cancer. Anti-Cancer Research. https://doi.org/10.21873/anticanres.13508 (hassouni2019uridinecytidinekinase pages 1-2)
Mashayekh S. et al. (Oct 2022). Structure-based prototyping of allosteric inhibitors of human UCK2. Biochemistry. https://doi.org/10.1021/acs.biochem.2c00451 (mashayekh2022structurebasedprototypingof pages 1-6)
Okesli-Armlovich A. et al. (Sep 2019). Discovery of small-molecule inhibitors of human UCK2. Bioorg Med Chem Lett. https://doi.org/10.1016/j.bmcl.2019.08.010 (okesliarmlovich2019discoveryofsmall pages 1-3)

13) Summary conclusion

Human UCK2 (Q9BZX2) is a pyrimidine ribonucleoside kinase that catalyzes ATP-dependent phosphorylation of uridine and cytidine to UMP and CMP, showing high selectivity for ribonucleosides and strong structural regulation via tetrameric conformational states and feedback inhibition by UTP/CTP. Modern research (2023–2024) increasingly links UCK2 to clinically relevant phenotypes—especially cancer proliferation/therapy response and nucleoside analog activation—supporting its dual importance as a metabolic node and as a drug-activation/biomarker axis, while also motivating ongoing development of allosteric and non-competitive inhibitors for antiviral and cancer-adjacent applications. (suzuki2004structuralbasisfor pages 1-3, rompay2001phosphorylationofuridine pages 3-4, xu2023uridine–cytidinekinase2 pages 9-10, wu2024uck2promotesintrahepatic pages 1-2)

References

(suzuki2004structuralbasisfor pages 1-3): N. Suzuki, K. Koizumi, M. Fukushima, A. Matsuda, and F. Inagaki. Structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase. Structure, 12 5:751-64, May 2004. URL: https://doi.org/10.1016/j.str.2004.02.038, doi:10.1016/j.str.2004.02.038. This article has 108 citations and is from a domain leading peer-reviewed journal.
(sarkisjan2016thecytidineanalog pages 1-2): Dzjemma Sarkisjan, Joris R. Julsing, Kees Smid, Daniël de Klerk, André B. P. van Kuilenburg, Rutger Meinsma, Young B. Lee, Deog J. Kim, and Godefridus J. Peters. The cytidine analog fluorocyclopentenylcytosine (rx-3117) is activated by uridine-cytidine kinase 2. PLoS ONE, 11:e0162901, Sep 2016. URL: https://doi.org/10.1371/journal.pone.0162901, doi:10.1371/journal.pone.0162901. This article has 34 citations and is from a peer-reviewed journal.
(mashayekh2022structurebasedprototypingof pages 6-12): Siavash Mashayekh, Lee M. Stunkard, Maryline Kienle, Irimpan I. Mathews, and Chaitan Khosla. Structure-based prototyping of allosteric inhibitors of human uridine/cytidine kinase 2 (uck2). Biochemistry, 61:2261-2266, Oct 2022. URL: https://doi.org/10.1021/acs.biochem.2c00451, doi:10.1021/acs.biochem.2c00451. This article has 1 citations and is from a peer-reviewed journal.
(okesliarmlovich2019discoveryofsmall pages 1-3): Ayse Okesli-Armlovich, Amita Gupta, Marta Jimenez, Douglas Auld, Qi Liu, Michael C. Bassik, and Chaitan Khosla. Discovery of small molecule inhibitors of human uridine-cytidine kinase 2 by high-throughput screening. Sep 2019. URL: https://doi.org/10.1016/j.bmcl.2019.08.010, doi:10.1016/j.bmcl.2019.08.010. This article has 19 citations and is from a peer-reviewed journal.
(rompay2001phosphorylationofuridine pages 3-4): An R. Van Rompay, Ameli Norda, Karin Lindén, Magnus Johansson, and Anna Karlsson. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Molecular pharmacology, 59 5:1181-6, May 2001. URL: https://doi.org/10.1124/mol.59.5.1181, doi:10.1124/mol.59.5.1181. This article has 220 citations and is from a domain leading peer-reviewed journal.
(suzuki2004structuralbasisfor pages 4-6): N. Suzuki, K. Koizumi, M. Fukushima, A. Matsuda, and F. Inagaki. Structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase. Structure, 12 5:751-64, May 2004. URL: https://doi.org/10.1016/j.str.2004.02.038, doi:10.1016/j.str.2004.02.038. This article has 108 citations and is from a domain leading peer-reviewed journal.
(suzuki2004structuralbasisfor media fedd12be): N. Suzuki, K. Koizumi, M. Fukushima, A. Matsuda, and F. Inagaki. Structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase. Structure, 12 5:751-64, May 2004. URL: https://doi.org/10.1016/j.str.2004.02.038, doi:10.1016/j.str.2004.02.038. This article has 108 citations and is from a domain leading peer-reviewed journal.
(suzuki2004structuralbasisfor media da16ea3f): N. Suzuki, K. Koizumi, M. Fukushima, A. Matsuda, and F. Inagaki. Structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase. Structure, 12 5:751-64, May 2004. URL: https://doi.org/10.1016/j.str.2004.02.038, doi:10.1016/j.str.2004.02.038. This article has 108 citations and is from a domain leading peer-reviewed journal.
(suzuki2004structuralbasisfor media 76e0d74f): N. Suzuki, K. Koizumi, M. Fukushima, A. Matsuda, and F. Inagaki. Structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase. Structure, 12 5:751-64, May 2004. URL: https://doi.org/10.1016/j.str.2004.02.038, doi:10.1016/j.str.2004.02.038. This article has 108 citations and is from a domain leading peer-reviewed journal.
(suzuki2004structuralbasisfor media 4a76c853): N. Suzuki, K. Koizumi, M. Fukushima, A. Matsuda, and F. Inagaki. Structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase. Structure, 12 5:751-64, May 2004. URL: https://doi.org/10.1016/j.str.2004.02.038, doi:10.1016/j.str.2004.02.038. This article has 108 citations and is from a domain leading peer-reviewed journal.
(mashayekh2022structurebasedprototypingof pages 1-6): Siavash Mashayekh, Lee M. Stunkard, Maryline Kienle, Irimpan I. Mathews, and Chaitan Khosla. Structure-based prototyping of allosteric inhibitors of human uridine/cytidine kinase 2 (uck2). Biochemistry, 61:2261-2266, Oct 2022. URL: https://doi.org/10.1021/acs.biochem.2c00451, doi:10.1021/acs.biochem.2c00451. This article has 1 citations and is from a peer-reviewed journal.
(hassouni2019uridinecytidinekinase pages 1-2): BTISSAME EL HASSOUNI, JESSICA INFANTE, GIULIA MANTINI, CLAUDIO RICCI, NICCOLA FUNEL, ELISA GIOVANNETTI, and GODEFRIDUS J. PETERS. Uridine cytidine kinase 2 as a potential biomarker for treatment with rx-3117 in pancreatic cancer*. AntiCancer Research, 39:3609-3614, Jul 2019. URL: https://doi.org/10.21873/anticanres.13508, doi:10.21873/anticanres.13508. This article has 14 citations and is from a peer-reviewed journal.
(fu2022themetabolicand pages 2-4): Yi Fu, Xin-dong Wei, Luoting Guo, Kai Wu, Jiamei Le, Yujie Ma, Xiaoni Kong, Ying Tong, and Hailong Wu. The metabolic and non-metabolic roles of uck2 in tumor progression. Frontiers in Oncology, May 2022. URL: https://doi.org/10.3389/fonc.2022.904887, doi:10.3389/fonc.2022.904887. This article has 34 citations.
(xu2023uridine–cytidinekinase2 pages 9-10): Zhen Xu, Christoffer Flensburg, Rebecca A Bilardi, and Ian J Majewski. Uridine–cytidine kinase 2 potentiates the mutagenic influence of the antiviral β-d-n4-hydroxycytidine. Nucleic Acids Research, 51:12031-12042, Nov 2023. URL: https://doi.org/10.1093/nar/gkad1002, doi:10.1093/nar/gkad1002. This article has 13 citations and is from a highest quality peer-reviewed journal.
(li2024integrativeanalysesof pages 1-2): Yin Li, Manling Jiang, Yongqi Wei, Xiang He, Guoping Li, Chunlai Lu, and Di Ge. Integrative analyses of pyrimidine salvage pathway-related genes revealing the associations between upp1 and tumor microenvironment. Journal of Inflammation Research, 17:101-119, Jan 2024. URL: https://doi.org/10.2147/jir.s440295, doi:10.2147/jir.s440295. This article has 10 citations and is from a peer-reviewed journal.
(watanabe2024reprogrammingofpyrimidine pages 6-7): Tatsuro Watanabe, Yuta Yamamoto, Yuki Kurahashi, Kazunori Kawasoe, Keisuke Kidoguchi, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Hideaki Nakamura, Seiji Okada, Eisaburo Sueoka, and Shinya Kimura. Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant t cells. Blood Advances, 8:1345-1358, Mar 2024. URL: https://doi.org/10.1182/bloodadvances.2023011131, doi:10.1182/bloodadvances.2023011131. This article has 9 citations and is from a peer-reviewed journal.
(wu2024uck2promotesintrahepatic pages 1-2): Xiwen Wu, Da Chen, Muqi Li, Gehao Liang, and Huizhen Ye. Uck2 promotes intrahepatic cholangiocarcinoma progression and desensitizes cisplatin treatment by pi3k/akt/mtor/autophagic axis. Cell Death Discovery, Aug 2024. URL: https://doi.org/10.1038/s41420-024-02140-x, doi:10.1038/s41420-024-02140-x. This article has 11 citations and is from a peer-reviewed journal.
(shen2024circuck2promoteshepatocellular pages 1-3): Minghai Shen, Qinghua Zhang, Wanneng Pan, and Bei Wang. Circuck2 promotes hepatocellular carcinoma development by upregulating uck2 in a mir-149-5p-dependent manner. Discover. Oncology, Jan 2024. URL: https://doi.org/10.1007/s12672-024-00863-y, doi:10.1007/s12672-024-00863-y. This article has 2 citations.
(okesliarmlovich2019discoveryofsmall pages 4-6): Ayse Okesli-Armlovich, Amita Gupta, Marta Jimenez, Douglas Auld, Qi Liu, Michael C. Bassik, and Chaitan Khosla. Discovery of small molecule inhibitors of human uridine-cytidine kinase 2 by high-throughput screening. Sep 2019. URL: https://doi.org/10.1016/j.bmcl.2019.08.010, doi:10.1016/j.bmcl.2019.08.010. This article has 19 citations and is from a peer-reviewed journal.
(fu2022themetabolicand pages 1-2): Yi Fu, Xin-dong Wei, Luoting Guo, Kai Wu, Jiamei Le, Yujie Ma, Xiaoni Kong, Ying Tong, and Hailong Wu. The metabolic and non-metabolic roles of uck2 in tumor progression. Frontiers in Oncology, May 2022. URL: https://doi.org/10.3389/fonc.2022.904887, doi:10.3389/fonc.2022.904887. This article has 34 citations.

Artifacts

Edison artifact artifact-00

Citations

rompay2001phosphorylationofuridine pages 3-4
suzuki2004structuralbasisfor pages 1-3
suzuki2004structuralbasisfor pages 4-6
li2024integrativeanalysesof pages 1-2
watanabe2024reprogrammingofpyrimidine pages 6-7
sarkisjan2016thecytidineanalog pages 1-2
hassouni2019uridinecytidinekinase pages 1-2
okesliarmlovich2019discoveryofsmall pages 4-6
okesliarmlovich2019discoveryofsmall pages 1-3
mashayekh2022structurebasedprototypingof pages 1-6
mashayekh2022structurebasedprototypingof pages 6-12
fu2022themetabolicand pages 2-4
fu2022themetabolicand pages 1-2
https://doi.org/10.1093/nar/gkad1002
https://doi.org/10.1182/bloodadvances.2023011131
https://doi.org/10.1038/s41420-024-02140-x
https://doi.org/10.1007/s12672-024-00863-y
https://doi.org/10.1016/j.str.2004.02.038;
https://doi.org/10.3389/fonc.2022.904887;
https://doi.org/10.1016/j.bmcl.2019.08.010
https://doi.org/10.1124/mol.59.5.1181;
https://doi.org/10.3389/fonc.2022.904887
https://doi.org/10.1021/acs.biochem.2c00451
https://doi.org/10.21873/anticanres.13508;
https://doi.org/10.1093/nar/gkad1002;
https://doi.org/10.2147/jir.s440295
https://doi.org/10.1182/bloodadvances.2023011131;
https://doi.org/10.1038/s41420-024-02140-x;
https://doi.org/10.2147/jir.s440295;
https://doi.org/10.1371/journal.pone.0162901;
https://doi.org/10.1016/j.bmcl.2019.08.010;
https://doi.org/10.1021/acs.biochem.2c00451;
https://doi.org/10.1016/j.str.2004.02.038
https://doi.org/10.1124/mol.59.5.1181
https://doi.org/10.1371/journal.pone.0162901
https://doi.org/10.21873/anticanres.13508
https://doi.org/10.1016/j.str.2004.02.038,
https://doi.org/10.1371/journal.pone.0162901,
https://doi.org/10.1021/acs.biochem.2c00451,
https://doi.org/10.1016/j.bmcl.2019.08.010,
https://doi.org/10.1124/mol.59.5.1181,
https://doi.org/10.21873/anticanres.13508,
https://doi.org/10.3389/fonc.2022.904887,
https://doi.org/10.1093/nar/gkad1002,
https://doi.org/10.2147/jir.s440295,
https://doi.org/10.1182/bloodadvances.2023011131,
https://doi.org/10.1038/s41420-024-02140-x,
https://doi.org/10.1007/s12672-024-00863-y,

Perplexity

(UCK2-deep-research-perplexity-lite.md)

1. Key Concepts and Definitions Perplexity sonar-pro 11 citations 2025-11-15T18:18:43.409617

Uridine-Cytidine Kinase 2 (UCK2) is a human gene encoding a key enzyme in the pyrimidine salvage pathway, with important roles in nucleotide metabolism, cancer biology, and cellular signaling.

1. Key Concepts and Definitions

Molecular Function:
UCK2 encodes a pyrimidine ribonucleoside kinase that catalyzes the phosphorylation of uridine and cytidine to uridine monophosphate (UMP) and cytidine monophosphate (CMP), respectively, using ATP or GTP as phosphate donors[1][5][8][10].
Enzyme Commission (EC) number: 2.7.1.48[1][5].
Gene Ontology (GO) annotations: Cytidine kinase activity, uridine kinase activity, and identical protein binding activity[11].
Biological Processes:
UCK2 is central to the pyrimidine salvage pathway, which recycles nucleosides for RNA and DNA synthesis[1][2][3][8].
Involved in CTP salvage and UMP salvage[11].
Plays a role in ribosomal biogenesis and cellular response to nucleolar stress[2][3].
Cellular Localization:
UCK2 is primarily cytoplasmic[5].
Expression is tissue-specific: highly expressed in placenta and various cancers, but not in most normal adult tissues[2][3][7].

2. Protein Domains and Structure

Structural Features:
UCK2 is a tetramer (~112 kDa total)[3].
Each monomer contains:
- A five-stranded parallel β-sheet (core)
- Five α-helices
- A large β-hairpin loop forming a deep substrate binding pocket[2][3]
Active site residues:
- Asp-62: Catalytic activity, deprotonates the 5’-hydroxyl group of the substrate[3].
- His117 and Tyr112: Determine nucleoside binding specificity via hydrogen bonds[2].
Substrate specificity:
- UCK2 is specific for ribonucleosides (uridine, cytidine), not 2’-deoxyribonucleosides[3].

3. Known Interactions

Protein-Protein Interactions:
UCK2 interacts with EGFR (Epidermal Growth Factor Receptor), blocking EGF-induced EGFR ubiquitination and degradation, thereby activating the EGFR-AKT signaling pathway[2].
UCK2 inhibition leads to nucleolar stress, releasing ribosomal proteins that bind MDM2, blocking p53 ubiquitination and activating p53-mediated apoptosis[2][3].
Pathways:
Nucleotide salvage
Fluoropyrimidine activity (activation of nucleoside analog drugs)[1][3]

4. Disease Associations

Cancer:
Overexpression of UCK2 is observed in multiple cancers, including:
- Lung cancer (especially small cell lung carcinoma)[1][4]
- Hepatocellular carcinoma (HCC)[1][2][4]
- Esophageal, liver, pancreatic, gastric, renal, nasopharyngeal, colorectal cancers, and pediatric T-cell acute lymphatic leukemia[4]
Prognostic marker: High UCK2 expression correlates with poor prognosis and reduced survival rates in several cancers[4].
Functional role: Promotes cell proliferation, migration, and metastasis via activation of oncogenic pathways (e.g., STAT3, MMP2, MMP9)[3][4].
Therapeutic target: UCK2 is being explored as a target for anti-cancer therapies, either by inhibiting its activity or exploiting its role in activating nucleoside analog drugs[2][3].
Other Associations:
An allele of UCK2 may play a role in nonhumoral immunity to Haemophilus influenzae type B[3].

5. Recent Developments and Latest Research (2022–2024)

Non-metabolic roles:
UCK2 has non-metabolic functions in tumor progression, such as interacting with EGFR and modulating signaling pathways[2].
UCK2 can generate circular RNAs with potential tumor-suppressive roles[2].
Biomarker potential:
UCK2 is being investigated as an early diagnostic and prognostic biomarker for lung cancer and other malignancies[4].
Therapeutic implications:
Inhibition of UCK2 can induce nucleolar stress and p53-mediated apoptosis in cancer cells, suggesting a strategy for cancer therapy[2][3].

6. Relevant Statistics and Data

Sequence identity:
UCK2 shares 72% sequence identity with UCK1[2][3].
Catalytic efficiency: UCK2 is 15–20 times higher than UCK1[2].
Genomic location:
Chromosome 1q22-23.2 (positions 165,827,586–165,911,618, forward strand)[4][9].

7. Authoritative Sources and URLs

Summary:
UCK2 is a cytoplasmic kinase essential for pyrimidine salvage, with a unique structure and high catalytic efficiency. It is overexpressed in many cancers, where it promotes tumor progression through both metabolic and non-metabolic mechanisms, making it a promising biomarker and therapeutic target[1][2][3][4][5].

Citations

https://www.genecards.org/cgi-bin/carddisp.pl?gene=UCK2
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.904887/full
https://en.wikipedia.org/wiki/UCK2
https://pmc.ncbi.nlm.nih.gov/articles/PMC6726693/
https://www.uniprot.org/uniprotkb/Q9BZX2/entry
https://www.proteinatlas.org/ENSG00000143179-UCK2
https://www.proteinatlas.org/ENSG00000143179-UCK2/tissue
https://maayanlab.cloud/Harmonizome/gene/UCK2
https://www.ensembl.org/id/ENSG00000143179.16
http://biogps.org/gene/7371/
https://www.alliancegenome.org/gene/HGNC:12562

📄 View Raw YAML

id: Q9BZX2
gene_symbol: UCK2
product_type: PROTEIN
status: COMPLETE
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: Uridine-cytidine kinase 2 (UCK2) is a cytosolic pyrimidine ribonucleoside
  kinase that catalyzes the phosphorylation of uridine and cytidine to their respective
  monophosphates (UMP and CMP) using ATP or GTP as phosphate donors. UCK2 is a key
  enzyme in the pyrimidine salvage pathway, essential for nucleotide metabolism and
  RNA/DNA synthesis. The enzyme functions as a homotetramer and exhibits substrate
  specificity for ribonucleosides, not deoxyribonucleosides. UCK2 also activates cytotoxic
  nucleoside analogs used in cancer chemotherapy. Expression is tissue-specific, with
  high levels in placenta and various cancers.
existing_annotations:
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: IBA annotation correctly places UCK2 in the cytoplasm. Multiple lines
      of evidence confirm cytoplasmic localization, including Reactome annotation
      as cytosolic enzyme and experimental data showing cytosol localization in transfected
      cells.
    action: ACCEPT
    reason: Consistent with experimental evidence from multiple sources confirming
      cytoplasmic/cytosolic localization. UniProt CC line states function occurs in
      cytoplasm, Reactome describes enzyme as cytosolic, and direct fluorescence microscopy
      shows cytosol localization.
    supported_by:
    - reference_id: PMID:27239701
      supporting_text: Subcellular localization studies showed that UCK1-GFP and UCK2-GFP
        were localized in the cell nucleus and cytosol, respectively.
    - reference_id: Reactome:R-HSA-109903
      supporting_text: Cytosolic uridine-cytidine kinase 2 (UCK2) catalyzes the reactions
        of cytidine or uridine with ATP to form CMP or UMP and ADP
    - reference_id: file:human/UCK2/UCK2-deep-research-perplexity-lite.md
      supporting_text: See deep research file for comprehensive analysis
    - reference_id: file:human/UCK2/UCK2-deep-research-falcon.md
      supporting_text: cytosolic pyrimidine nucleoside salvage
      reference_section_type: DISCUSSION
- term:
    id: GO:0004849
    label: uridine kinase activity
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: IBA annotation for uridine kinase activity is well-supported. UCK2 catalyzes
      phosphorylation of uridine to UMP using ATP. This is one of the two core catalytic
      activities of UCK2.
    action: ACCEPT
    reason: This represents a core molecular function of UCK2, supported by direct
      experimental evidence and multiple independent studies. UniProt catalytic activity
      annotation confirms this function with EC 2.7.1.48.
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: The enzymes did not phosphorylate deoxyribonucleosides or purine
        ribonucleosides. UCK1 mRNA was detected as two isoforms... The enzymes phosphorylated
        several of the analogs, such as 6-azauridine, 5-fluorouridine
    - reference_id: PMID:27239701
      supporting_text: Uridine-cytidine kinase (UCK) catalyzes the phosphorylation
        of uridine and cytidine
    - reference_id: file:human/UCK2/UCK2-deep-research-falcon.md
      supporting_text: |-
        Human UCK2 (UniProt Q9BZX2; EC 2.7.1.48) catalyzes ATP-dependent
        phosphorylation of the pyrimidine ribonucleosides uridine and cytidine to
        UMP and CMP, respectively, constituting the first/rate-limiting step of
        pyrimidine ribonucleoside salvage in many settings.
      reference_section_type: RESULTS
- term:
    id: GO:0009224
    label: CMP biosynthetic process
  evidence_type: IEA
  original_reference_id: GO_REF:0000108
  review:
    summary: IEA annotation for CMP biosynthetic process based on logical inference
      from cytidine kinase activity. While technically correct (UCK2 does synthesize
      CMP from cytidine), this term is overly general as it does not distinguish between
      de novo and salvage pathways. The more specific term GO:0044211 (CTP salvage)
      better captures UCK2's specific role in the salvage pathway.
    action: MODIFY
    reason: The term is too general and does not accurately reflect that UCK2 functions
      specifically in the salvage pathway, not de novo biosynthesis. UCK2 catalyzes
      cytidine + ATP to CMP + ADP, which is the first step of CTP salvage. The annotation
      should use GO:0044211 (CTP salvage) which is already present with IDA evidence.
    proposed_replacement_terms:
    - id: GO:0044211
      label: CTP salvage
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: shown to catalyze the phosphorylation of Urd and Cyd
    - reference_id: file:human/UCK2/UCK2-uniprot.txt
      supporting_text: 'Pyrimidine metabolism; CTP biosynthesis via salvage pathway;
        CTP from cytidine: step 1/3'
- term:
    id: GO:0000166
    label: nucleotide binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: This is a very general molecular function term. While UCK2 does bind
      nucleotides (ATP/GTP as phosphate donors, and uridine/cytidine substrates),
      this annotation is too non-specific to be informative. The more specific ATP
      binding term (GO:0005524) is already present.
    action: MARK_AS_OVER_ANNOTATED
    reason: This term is too general and does not provide meaningful information about
      UCK2 specific function. The GO:0005524 (ATP binding) annotation is more informative
      and specific. Nucleotide binding is implied by the kinase activity annotations.
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: named UCK1 and UCK2, were expressed in Escherichia coli and
        shown to catalyze the phosphorylation of Urd and Cyd
- term:
    id: GO:0004849
    label: uridine kinase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: Duplicate annotation of uridine kinase activity with different evidence
      code. This IEA annotation is redundant with the IBA and IDA annotations for
      the same term.
    action: ACCEPT
    reason: While redundant, computational annotations can coexist with experimental
      ones. The annotation is correct and represents a core function of UCK2.
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: The enzymes did not phosphorylate deoxyribonucleosides or purine
        ribonucleosides... catalyze the phosphorylation of Urd and Cyd
- term:
    id: GO:0005524
    label: ATP binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: UCK2 uses ATP (or GTP) as a phosphate donor in its kinase reactions.
      Crystal structures show ATP binding sites. This is an essential component of
      UCK2 catalytic mechanism.
    action: ACCEPT
    reason: ATP binding is a core molecular function required for UCK2 kinase activity.
      Supported by structural data showing ATP binding sites and biochemical evidence
      that ATP serves as phosphate donor.
    supported_by:
    - reference_id: Reactome:R-HSA-109903
      supporting_text: cytidine or uridine with ATP to form CMP or UMP and ADP
    - reference_id: file:human/UCK2/UCK2-deep-research-falcon.md
      supporting_text: with ATP serving as the phosphate donor.
      reference_section_type: RESULTS
- term:
    id: GO:0016301
    label: kinase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: General kinase activity term that is less specific than the actual uridine
      kinase and cytidine kinase activities already annotated. While technically correct,
      it provides little additional information.
    action: MARK_AS_OVER_ANNOTATED
    reason: This is a parent term of the more specific uridine kinase and cytidine
      kinase activities. The specific terms (GO:0004849, GO:0043771) provide more
      informative annotations. General parent terms like this are often automatically
      inferred but do not add functional specificity.
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: shown to catalyze the phosphorylation of Urd and Cyd
- term:
    id: GO:0016740
    label: transferase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: Extremely general molecular function term. Kinases are indeed transferases
      (transferring phosphate groups), but this term is far too broad to be informative
      about UCK2 specific function.
    action: MARK_AS_OVER_ANNOTATED
    reason: This is a very high-level parent term that provides minimal functional
      information. The specific kinase activity terms are far more informative. Such
      general terms are typically auto-generated but do not contribute meaningful
      biological insight.
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: catalyze the phosphorylation of Urd and Cyd
- term:
    id: GO:0043771
    label: cytidine kinase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: Cytidine kinase activity is one of the two core catalytic activities
      of UCK2, converting cytidine to CMP. This is well-documented experimentally.
    action: ACCEPT
    reason: This represents a core molecular function of UCK2, equally important as
      its uridine kinase activity. Both activities are confirmed by direct biochemical
      assays and structural studies.
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: catalyze the phosphorylation of Urd and Cyd. The enzymes did
        not phosphorylate deoxyribonucleosides or purine ribonucleosides
    - reference_id: file:human/UCK2/UCK2-deep-research-falcon.md
      supporting_text: |-
        UCK2 is selective for pyrimidine ribonucleosides and does not
        phosphorylate purine ribonucleosides or 2′-deoxyribonucleosides
      reference_section_type: RESULTS
- term:
    id: GO:0007631
    label: feeding behavior
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: This annotation appears to be a computational transfer from orthologs
      and is likely spurious for UCK2. There is no literature evidence connecting
      UCK2 to feeding behavior, and this seems implausible for a cytosolic nucleoside
      kinase involved in nucleotide metabolism.
    action: REMOVE
    reason: |-
      No supporting evidence for UCK2 involvement in feeding behavior. This
      appears to be an incorrect orthology-based inference. The deep research and
      all publications focus on nucleotide metabolism, cancer biology, and drug activation,
      with no mention of feeding behavior. The falcon deep research, which surveyed
      foundational enzymology through 2024 cancer/antiviral literature, likewise
      describes UCK2 exclusively as a pyrimidine ribonucleoside salvage kinase with
      no feeding-behavior role, reinforcing that this is a false positive from
      automated annotation transfer.
    supported_by:
    - reference_id: file:human/UCK2/UCK2-deep-research-falcon.md
      supporting_text: |-
        Human UCK2 (UniProt Q9BZX2; EC 2.7.1.48) catalyzes ATP-dependent
        phosphorylation of the pyrimidine ribonucleosides uridine and cytidine to
        UMP and CMP, respectively, constituting the first/rate-limiting step of
        pyrimidine ribonucleoside salvage in many settings.
      reference_section_type: RESULTS
- term:
    id: GO:0048678
    label: response to axon injury
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: This annotation is based on automated ortholog transfer. While UCK2 is
      expressed in neural tissues and has been studied in neuroblastoma, there is
      no direct evidence linking it to axon injury response. This may be an overly
      specific inference from expression data.
    action: UNDECIDED
    reason: No direct experimental evidence in the available literature for UCK2 role
      in axon injury response. The neuroblastoma study focuses on UCK2 role in pyrimidine
      metabolism and drug sensitivity, not axon injury. Would need access to the original
      ortholog study (GO_REF:0000107) to evaluate this claim properly.
- term:
    id: GO:0071453
    label: cellular response to oxygen levels
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: This annotation comes from automated ortholog transfer. There is no direct
      evidence in the available literature connecting UCK2 to oxygen level response.
      While UCK2 is overexpressed in various cancers which may involve hypoxic conditions,
      this is not the same as having a specific role in oxygen level response.
    action: UNDECIDED
    reason: No direct experimental evidence in available publications for UCK2 role
      in cellular response to oxygen levels. Would need to access the original reference
      and any supporting ortholog data to properly evaluate this annotation. The cancer
      association does not necessarily imply a direct oxygen response function.
- term:
    id: GO:0042802
    label: identical protein binding
  evidence_type: IPI
  original_reference_id: PMID:32296183
  review:
    summary: This IPI annotation comes from the HuRI human reference interactome study,
      a large-scale yeast two-hybrid screen that detected UCK2 self-interaction. This
      is fully consistent with crystallographic data showing UCK2 functions as a homotetramer
      in its active form.
    action: ACCEPT
    reason: UCK2 forms homotetramers, which necessarily involves identical protein
      binding. This is strongly supported by X-ray crystallographic structures (PDB
      entries 1UDW, 1UEI, 1UEJ, 1UFQ, etc.) showing the tetrameric assembly and the
      HuRI binary interaction data confirming self-interaction. The functional oligomerization
      state is well-established as essential for enzymatic activity.
    supported_by:
    - reference_id: PMID:32296183
      supporting_text: (#)Contributed equally Global insights into cellular organization
        and genome function require comprehensive understanding of the interactome
        networks that mediate genotype-phenotype relationships1,2
    - reference_id: file:human/UCK2/UCK2-uniprot.txt
      supporting_text: 'SUBUNIT: Homotetramer'
    - reference_id: file:human/UCK2/UCK2-deep-research-falcon.md
      supporting_text: |-
        UCK2 is a ~29 kDa, 261-aa enzyme in the NMP kinase-fold family that forms
        a homotetramer
      reference_section_type: RESULTS
    additional_reference_ids:
    - PMID:15130468
    - PMID:15735337
- term:
    id: GO:0044206
    label: UMP salvage
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: UMP salvage is a core biological process function of UCK2. The enzyme
      catalyzes the first and only step in converting uridine to UMP in the salvage
      pathway.
    action: ACCEPT
    reason: This is a core biological process for UCK2, converting uridine to UMP
      in the salvage pathway. Well-supported by experimental data and pathway annotations.
      This is redundant with IDA annotations below but represents accurate function.
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: catalyze the phosphorylation of Urd and Cyd
    - reference_id: Reactome:R-HSA-109903
      supporting_text: cytidine or uridine with ATP to form CMP or UMP and ADP
    - reference_id: file:human/UCK2/UCK2-deep-research-falcon.md
      supporting_text: |-
        UCK2 catalyzes the first committed phosphorylation step
      reference_section_type: RESULTS
- term:
    id: GO:0044211
    label: CTP salvage
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: CTP salvage is a core biological process function of UCK2. UCK2 catalyzes
      the first step (cytidine to CMP) in the three-step salvage pathway converting
      cytidine to CTP.
    action: ACCEPT
    reason: This is a core biological process for UCK2. The enzyme performs the first
      step in the salvage pathway that recycles cytidine into CTP. Well-supported
      by experimental evidence and pathway databases. Redundant with IDA annotation
      below but accurate.
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: catalyze the phosphorylation of Urd and Cyd
    - reference_id: Reactome:R-HSA-109903
      supporting_text: cytidine or uridine with ATP to form CMP or UMP and ADP
    - reference_id: file:human/UCK2/UCK2-deep-research-falcon.md
      supporting_text: |-
        UCK2 catalyzes the first committed phosphorylation step
      reference_section_type: RESULTS
- term:
    id: GO:0004849
    label: uridine kinase activity
  evidence_type: IDA
  original_reference_id: PMID:27239701
  review:
    summary: Direct experimental evidence for uridine kinase activity from neuroblastoma
      study. This IDA annotation provides strong experimental support for this core
      function.
    action: ACCEPT
    reason: Excellent experimental support from direct assay. This is a core molecular
      function of UCK2. The IDA evidence code indicates direct biochemical demonstration
      of this activity.
    supported_by:
    - reference_id: PMID:27239701
      supporting_text: Uridine-cytidine kinase (UCK) catalyzes the phosphorylation
        of uridine and cytidine as well as the pharmacological activation of several
        cytotoxic pyrimidine ribonucleoside analogues
- term:
    id: GO:0044206
    label: UMP salvage
  evidence_type: IDA
  original_reference_id: PMID:27239701
  review:
    summary: Direct experimental evidence for UMP salvage from neuroblastoma study
      showing UCK2 metabolizes uridine. Strong experimental support for this core
      biological process.
    action: ACCEPT
    reason: Excellent experimental support from direct functional assays in neuroblastoma
      cells. The study directly measured uridine metabolism via UCK2, demonstrating
      its role in UMP salvage. This is a core biological process for UCK2.
    supported_by:
    - reference_id: PMID:27239701
      supporting_text: Transient and stable overexpression of UCK2 in neuroblastoma
        cells increased the metabolism of uridine and cytidine
- term:
    id: GO:0004849
    label: uridine kinase activity
  evidence_type: IDA
  original_reference_id: PMID:11306702
  review:
    summary: Direct experimental evidence from the original cloning and characterization
      study. This is the foundational paper demonstrating UCK2 uridine kinase activity.
    action: ACCEPT
    reason: This is the primary experimental characterization of UCK2 uridine kinase
      activity from the original cloning study. Direct biochemical demonstration of
      this core molecular function with recombinant enzyme.
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: The approximately 30-kDa proteins, named UCK1 and UCK2, were
        expressed in Escherichia coli and shown to catalyze the phosphorylation of
        Urd and Cyd. The enzymes did not phosphorylate deoxyribonucleosides or purine
        ribonucleosides
- term:
    id: GO:0043771
    label: cytidine kinase activity
  evidence_type: IDA
  original_reference_id: PMID:11306702
  review:
    summary: Direct experimental evidence from the original characterization study.
      This established cytidine kinase as one of the two core activities of UCK2.
    action: ACCEPT
    reason: Foundational experimental demonstration of UCK2 cytidine kinase activity
      from the original cloning and characterization study. Direct biochemical evidence
      with recombinant enzyme. This is a core molecular function.
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: shown to catalyze the phosphorylation of Urd and Cyd. The enzymes
        did not phosphorylate deoxyribonucleosides or purine ribonucleosides
- term:
    id: GO:0044206
    label: UMP salvage
  evidence_type: IDA
  original_reference_id: PMID:11306702
  review:
    summary: Direct experimental evidence for UMP salvage function from the original
      characterization showing uridine phosphorylation. This demonstrated UCK2 role
      in the salvage pathway.
    action: ACCEPT
    reason: Excellent experimental support from the foundational study. Direct demonstration
      that UCK2 phosphorylates uridine to UMP, which is the salvage pathway for UMP
      biosynthesis. This is a core biological process.
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: catalyze the phosphorylation of Urd and Cyd. The enzymes did
        not phosphorylate deoxyribonucleosides or purine ribonucleosides
- term:
    id: GO:0044211
    label: CTP salvage
  evidence_type: IDA
  original_reference_id: PMID:11306702
  review:
    summary: Direct experimental evidence for CTP salvage from the original study
      showing cytidine phosphorylation. UCK2 performs the first step in the CTP salvage
      pathway.
    action: ACCEPT
    reason: Strong experimental support from the foundational characterization study.
      Direct demonstration that UCK2 phosphorylates cytidine to CMP, the first step
      in CTP salvage pathway. This is a core biological process.
    supported_by:
    - reference_id: PMID:11306702
      supporting_text: catalyze the phosphorylation of Urd and Cyd
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-109903
  review:
    summary: TAS (Traceable Author Statement) annotation based on Reactome pathway
      annotation. Reactome describes UCK2 as cytosolic. This is consistent with experimental
      localization data.
    action: ACCEPT
    reason: Cytosol localization is well-supported by Reactome annotation and experimental
      evidence. While cytosol is a more specific term than cytoplasm (GO:0005737),
      both are appropriate. The TAS evidence from Reactome is reliable for subcellular
      localization.
    supported_by:
    - reference_id: Reactome:R-HSA-109903
      supporting_text: Cytosolic uridine-cytidine kinase 2 (UCK2) catalyzes the reactions
        of cytidine or uridine with ATP to form CMP or UMP and ADP
    - reference_id: PMID:27239701
      supporting_text: Subcellular localization studies showed that UCK1-GFP and UCK2-GFP
        were localized in the cell nucleus and cytosol, respectively
- term:
    id: GO:0005525
    label: GTP binding
  evidence_type: IDA
  original_reference_id: PMID:11306702
  review:
    summary: UCK2 can use GTP as an alternative phosphate donor in addition to ATP.
      This is documented in the original characterization study and in UniProt. While
      ATP is the primary phosphate donor, GTP binding represents an additional molecular
      function that provides metabolic flexibility.
    action: NEW
    reason: This represents a documented molecular function that is not currently
      annotated. The ability to use GTP as a phosphate donor is explicitly stated
      in UniProt and the original characterization paper. While less prominent than
      ATP binding, it represents a genuine alternative cofactor usage that should
      be annotated.
    supported_by:
    - reference_id: file:human/UCK2/UCK2-uniprot.txt
      supporting_text: Can use ATP or GTP as a phosphate donor
    - reference_id: PMID:11306702
      supporting_text: shown to catalyze the phosphorylation of Urd and Cyd
core_functions:
- description: ATP-dependent phosphorylation of uridine to UMP in pyrimidine salvage
    pathway
  molecular_function:
    id: GO:0004849
    label: uridine kinase activity
  directly_involved_in:
  - id: GO:0044206
    label: UMP salvage
  locations:
  - id: GO:0005829
    label: cytosol
  substrates:
  - id: CHEBI:16704
    label: uridine
  - id: CHEBI:30616
    label: ATP(4-)
  supported_by:
  - reference_id: PMID:11306702
    supporting_text: The approximately 30-kDa proteins, named UCK1 and UCK2, were
      expressed in Escherichia coli and shown to catalyze the phosphorylation of Urd
      and Cyd
  - reference_id: PMID:27239701
    supporting_text: Uridine-cytidine kinase (UCK) catalyzes the phosphorylation of
      uridine and cytidine as well as the pharmacological activation of several cytotoxic
      pyrimidine ribonucleoside analogues
  - reference_id: Reactome:R-HSA-109903
    supporting_text: Cytosolic uridine-cytidine kinase 2 (UCK2) catalyzes the reactions
      of cytidine or uridine with ATP to form CMP or UMP and ADP
  - reference_id: file:human/UCK2/UCK2-deep-research-falcon.md
    supporting_text: |-
      Human UCK2 (UniProt Q9BZX2; EC 2.7.1.48) catalyzes ATP-dependent
      phosphorylation of the pyrimidine ribonucleosides uridine and cytidine to
      UMP and CMP, respectively, constituting the first/rate-limiting step of
      pyrimidine ribonucleoside salvage in many settings.
    reference_section_type: RESULTS
- description: ATP-dependent phosphorylation of cytidine to CMP in pyrimidine salvage
    pathway
  molecular_function:
    id: GO:0043771
    label: cytidine kinase activity
  directly_involved_in:
  - id: GO:0044211
    label: CTP salvage
  locations:
  - id: GO:0005829
    label: cytosol
  substrates:
  - id: CHEBI:17562
    label: cytidine
  - id: CHEBI:30616
    label: ATP(4-)
  supported_by:
  - reference_id: PMID:11306702
    supporting_text: shown to catalyze the phosphorylation of Urd and Cyd. The enzymes
      did not phosphorylate deoxyribonucleosides or purine ribonucleosides
  - reference_id: PMID:27239701
    supporting_text: Transient and stable overexpression of UCK2 in neuroblastoma
      cells increased the metabolism of uridine and cytidine
  - reference_id: Reactome:R-HSA-109903
    supporting_text: Cytosolic uridine-cytidine kinase 2 (UCK2) catalyzes the reactions
      of cytidine or uridine with ATP to form CMP or UMP and ADP
  - reference_id: file:human/UCK2/UCK2-deep-research-falcon.md
    supporting_text: |-
      UCK2 is selective for pyrimidine ribonucleosides and does not phosphorylate
      purine ribonucleosides or 2′-deoxyribonucleosides
    reference_section_type: RESULTS
references:
- id: GO_REF:0000033
  title: Annotation inferences using phylogenetic trees
  findings: []
- id: GO_REF:0000043
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping
  findings: []
- id: GO_REF:0000107
  title: Automatic transfer of experimentally verified manual GO annotation data to
    orthologs using Ensembl Compara.
  findings: []
- id: GO_REF:0000108
  title: Automatic assignment of GO terms using logical inference, based on on inter-ontology
    links.
  findings: []
- id: GO_REF:0000120
  title: Combined Automated Annotation using Multiple IEA Methods.
  findings: []
- id: PMID:11306702
  title: Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine
    kinases.
  findings: []
- id: PMID:27239701
  title: The pivotal role of uridine-cytidine kinases in pyrimidine metabolism and
    activation of cytotoxic nucleoside analogues in neuroblastoma.
  findings: []
- id: PMID:32296183
  title: A reference map of the human binary protein interactome.
  findings: []
- id: Reactome:R-HSA-109903
  title: cytidine or uridine + ATP => CMP or UMP + ADP [UCK2]
  findings: []
- id: file:human/UCK2/UCK2-deep-research-perplexity-lite.md
  title: Deep research on UCK2 function
  findings: []
- id: file:human/UCK2/UCK2-deep-research-falcon.md
  title: Falcon deep research for human UCK2 (Q9BZX2)
  findings:
  - statement: |-
      UCK2 catalyzes the first committed, ATP-dependent phosphorylation step of
      pyrimidine ribonucleoside salvage, converting uridine to UMP and cytidine
      to CMP. This step is functionally rate-limiting for ribonucleoside salvage.
    supporting_text: |-
      UCK2 catalyzes the first committed phosphorylation step
    reference_section_type: RESULTS
  - statement: |-
      Substrate specificity is restricted to pyrimidine ribonucleosides: UCK2 does
      not phosphorylate purine ribonucleosides (adenosine/guanosine) or
      2'-deoxyribonucleosides, and accepts ribonucleoside analogs but not
      sugar-modified analogs such as araC, consistent with a ribose-OH requirement.
    supporting_text: |-
      UCK2 is selective for pyrimidine ribonucleosides and does not phosphorylate purine ribonucleosides or 2′-deoxyribonucleosides
    reference_section_type: RESULTS
  - statement: |-
      UCK2 has lower Km and higher Vmax (and thus markedly higher catalytic
      efficiency) for uridine and cytidine than the paralog UCK1.
    supporting_text: |-
      Compared with UCK1, UCK2 has lower Km and higher Vmax for uridine/cytidine
    reference_section_type: RESULTS
  - statement: |-
      UCK2 is a ~29 kDa, 261-residue enzyme of the NMP kinase fold that functions
      as a homotetramer, with crystal structures showing ligand-free, substrate/
      product-bound, and feedback-inhibited tetrameric states.
    supporting_text: |-
      UCK2 is a ~29 kDa, 261-aa enzyme in the NMP kinase-fold family that forms a homotetramer
    reference_section_type: RESULTS
  - statement: |-
      UCK2 is allosterically regulated: activated by ATP and feedback-inhibited by
      the downstream products UTP and CTP; a distinct intersubunit allosteric pocket
      has been described where noncompetitive inhibitors reduce kcat without changing Km.
    supporting_text: |-
      UCK2 is activated by ATP and feedback-inhibited by UTP and CTP.
    reference_section_type: RESULTS
  - statement: |-
      Localization is described as cytosolic pyrimidine nucleoside salvage, but the
      retrieved evidence set does not include direct microscopy-based localization
      experiments, so cytosolic localization is treated as a pathway-context inference.
    supporting_text: |-
      does not include direct microscopy-based localization experiments
    reference_section_type: DISCUSSION
  - statement: |-
      UCK2 is tissue-restricted in normal tissues (placenta/testis) but broadly
      upregulated across many cancers, motivating tumor-selective activation of
      cytotoxic nucleoside analogs (e.g., RX-3117) that depend on UCK2 phosphorylation.
    supporting_text: |-
      later translational studies and reviews describe expression in placenta/testis and broad upregulation across many cancers
    reference_section_type: DISCUSSION

Gene Description

Existing Annotations Review

Core Functions

ATP-dependent phosphorylation of uridine to UMP in pyrimidine salvage pathway

ATP-dependent phosphorylation of cytidine to CMP in pyrimidine salvage pathway

References

Deep Research

Falcon

Comprehensive Research Report: Human UCK2 (UniProt Q9BZX2) — Functional Annotation, Recent Research, and Applications

0) Target verification (gene/protein identity)

1) Key concepts and definitions (current understanding)

1.1 Pyrimidine nucleoside salvage and “rate-limiting” first phosphorylation

1.2 Enzymatic reaction catalyzed by UCK2

2) Core molecular function: substrates, specificity, and kinetics

2.1 Substrate class specificity (ribo vs deoxy; pyrimidine vs purine)

2.2 Quantitative kinetic differences: UCK2 vs UCK1

2.3 Nucleoside analog phosphorylation (drug/probe activation)

3) Structure, catalytic mechanism, and regulation

3.1 Oligomeric state and fold

3.2 Induced fit and binding-site remodeling

3.3 Feedback inhibition and nucleotide regulation

3.4 Allosteric inhibition: new structural insights (drug discovery relevance)

4) Cellular localization and pathway context

4.1 Subcellular location (evidence-limited)

4.2 Pathway interactions: salvage vs de novo synthesis

5) Expression patterns and regulation in normal tissues and cancer

5.1 Normal tissue expression (older panels) and tissue selectivity

5.2 2023 evidence of tissue-context relevance for drug genotoxicity

5.3 Pan-cancer genomic patterns (2024)

6) Recent developments (prioritizing 2023–2024)

6.1 UCK2 and antiviral nucleoside analog metabolism/genotoxicity (2023)

6.2 UCK2 induction in immune cell proliferation programs (2024)

6.3 UCK2 as a driver of tumor progression and chemotherapy response (2024)

6.4 Post-transcriptional regulation via circRNA (2024)

7) Current applications and real-world implementations

7.1 Precision oncology: UCK2 as a biomarker and drug-activation enzyme

7.2 Host-directed antiviral strategies: targeting salvage with UCK2 inhibitors

8) Expert opinions and synthesis from authoritative sources

9) Key statistics and quantitative data (from available evidence)

10) Limitations of the retrieved evidence set (important for functional annotation)

11) Consolidated evidence table

12) Key primary sources (with publication dates and URLs)

13) Summary conclusion

Artifacts

Citations

Perplexity

1. Key Concepts and Definitions

2. Protein Domains and Structure

3. Known Interactions

4. Disease Associations

5. Recent Developments and Latest Research (2022–2024)

6. Relevant Statistics and Data

7. Authoritative Sources and URLs

Citations

📄 View Raw YAML